Clinical Trial Update: Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating pharmacodynamic and pharmacokinetic effects of switching from cangrelor to prasugrel in acute coronary syndrome patients undergoing PCI…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome

Drugs mentioned

• Cangrelor (cangrelor)
• PRASUGREL (prasugrel)

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease, Acute Coronary Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2024-03-20